Taiyo Yakuhin Of Japan Secures Inventories To Ensure Stable Supply
This article was originally published in PharmAsia News
To prepare for upcoming changes in Japan's prescription drug forms, and anticipated increased competition in the generic drug business as a result of the change, Japanese generic drug giant, Nagoya-based Taiyo Yakuhin Co., announced it has secured a manufacturing inventory of seven and a half months and a retail inventory slightly over one and a half months of its 524 drug items. The move is also a follow up to Japan's Ministry of Health, Labor and Welfare's request of generic drug makers to secure a month's worth of both inventories. (Click here for more - Japanese language)
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”
With list due 4 November, there may not be time for public comment. Meanwhile, where will biopharma find fill/finish capacity?